NCT00513214已完成1 期
A Phase 1/2a, Double-blind, Placebo-controlled Study of the Safety and Pharmacokinetics of XOMA 052 in Subjects With Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 68
- 主要终点
- Safety assessed by pre- and post-treatment serial measurements of vital signs.
研究概览
简要总结
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of XOMA 052 in subjects with stable Type 2 Diabetes Mellitus (T2D).
The study is a dose-escalation study designed to evaluate route of administration (intravenous or subcutaneous), doses, and dosing regimens for future studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •American Diabetes Association (ADA) diagnostic criteria for T2D - Fasting blood glucose concentration ≥ 126 mg/dL (≥ 7.0 mmol/L) (must be measured within 35 days prior to Day 0) OR Symptoms of hyperglycemia (e.g., thirst, polyuria, weight loss, visual blurring) AND a casual/random plasma glucose value of ≥ 200 mg/dL (≥ 11.1 mmol/L) (must be measured within 35 days prior to Day 0)
- •HbA1c ≥ 7.5% and ≤ 12% (DCCT standard)
- •Current T2D of duration > 6 months at Screening
- •T2D and other diseases must be stable. Stable disease is defined as disease that is judged stable by the investigator and which did not require a change in medications or dosing level on 4 or more consecutive days or 7 days in total within 35 days prior to Day
- •Age ≥ 18 and ≤ 70 at Screening
- •Weight ≥ 80 lbs (36.3 kg) and ≤ 325 lbs (147.4 kg)
- •BMI ≥ 23 and ≤ 40 kg/m2
- •For female subjects of child-bearing age, a negative serum pregnancy test. For subjects with reproductive potential, a willingness to use contraceptive measures adequate to prevent the subject or the subject's partner from becoming pregnant during the study.
- •Agree not to change diet and exercise regimen during the trial
排除标准
- •Use of the following medications - Anti-inflammatory therapy other than aspirin ≤ 100 mg/day; Immunosuppressive treatment; Beta 2 and non-selective adrenergic blockers (Note: selective beta 1 blockers are permitted); Thiazolidinediones; Glucagon-like peptide (GLP) agonists including DPP4 inhibitors
- •Change in medication for diabetes within 35 days prior to Day 0, defined as a change in dosing level on 4 or more consecutive days or 7 days in total
- •Fasting C-peptide < 400 pM (< 1.20 μg/L)
- •Hemoglobin < 8.0 g/dL, WBC < 3.0 X 103/mm3, platelet count < 125 X 103/mm3, creatinine > 1.5 mg/dL, AST/ALT > 2 X ULN, alkaline phosphatase > 2 X ULN
- •Positive for GAD65 or IA-2 auto-antibodies
- •Known HIV antibody, hepatitis B surface antigen, and/or hepatitis C antibody
- •History of malignancy within 5 years prior to study entry other than carcinoma in situ of the cervix, or adequately treated, non-metastatic squamous or basal cell carcinoma of the skin
- •History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies
- •History of tuberculosis, positive PPD test, active atopic disease requiring medication, or asthma
- •Infectious disease - CRP > 30 mg/L, fever, or infection requiring treatment with antibiotics within 3 weeks prior to Screening; History of recurrent infection or predisposition to infection; Active leg or foot ulcer
- •Immunodeficiency
- •Female subjects who are pregnant, planning to become pregnant during the course of the study, or breast-feeding
- •History or symptoms of a demyelinating disease
- •Clinically significant diabetic macular edema and/or proliferative diabetic retinopathy by history or fundoscopy
- •Receipt of a live (attenuated) vaccine within 3 months prior to Screening
- •Major surgery within 35 days prior to Day 0
- •Participation in an investigational drug or device trial within 30 days prior to Screening
- •Use of a therapeutic monoclonal antibody within 90 days prior to Screening
- •Any condition which, in the opinion of the investigator, would jeopardize the subject's safety following exposure to the study drug
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
XOMA 052
Active Comparator
干预措施: XOMA 052 (Drug)
结局指标
主要结局
Safety assessed by pre- and post-treatment serial measurements of vital signs.
时间窗: Part 1: Day 0 pre-treatment through Day 56. Part 2: Day 0 pre-treatment through Day 56. Part 3: Day 0 pre-treatment through Day 84.
Safety assessed by treatment-emergent adverse events.
时间窗: Part 1: Day 0 post-treatment through Day 56. Part 2: Day 0 post-treatment through Day 56. Part 3: Day 0 post-treatment through Day 84.
次要结局
未报告次要终点
研究者
相似试验
暂停
2 期
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid ArthritisRheumatoid ArthritisNCT00777816XOMA (US) LLC18
已完成
2 期
A Single-Dose Open-Label Study of XOMA 358 in Subjects With Congenital HyperinsulinismCongenital HyperinsulinismNCT02604485XOMA (US) LLC10
已完成
2 期
Effects of XOMA 052 on Insulin Production in Type 1 DiabetesDiabetes Mellitus Type 1NCT01788033University of Zurich22
已完成
2 期
Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 DiabetesType 1 DiabetesNCT00998699XOMA (US) LLC22
已完成
2 期
Study of the Safety and Biologic Activity of XOMA 052 in Subjects With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT01144975XOMA (US) LLC76